In its September issue, Pharmaceutical Commerce details the previous and expected contributions of biologic products to its forecast of cold-chain market growth predicting sales of cold-chain drugs and biologics will outpace overall industry growth through 2022. It is reported that “as of 2018, global...
Wednesday, September 12, 2018 | Read More
In a recent news release the FDA described research it has conducted regarding detection of protein carbonylation, an oxidative reaction that may occur in therapeutic protein drug products during manufacture, storage, use, and transport potentially causing structural alterations and threatening stability,...
Tuesday, September 11, 2018 | Read More
Sentry BioPharma Services is pleased to announce delegates from Sentry’s Business Development team will be in New York City attending the Drug, Chemical & Associated Technologies Association (DCAT) Week March 19th -22nd. The four-day conference brings together key sourcing, procurement and business...
Monday, March 19, 2018 | Read More
Developing and delivering new drugs and biological products in a highly-regulated industry offers unique challenges to executives, project managers and functional managers alike. Sentry BioPharma Services' experienced team offers a practical and pragmatic approach to collaborate with its pharmaceutical clients to solve complex issues surrounding temperature-sensitive drug management and distribution while safeguarding drug safety, identity, strength, purity and quality (SISPQ). Areas of custom solutions are numerous. A few which Sentry highlights include:
Active pharmaceutical ingredients (APIs) and high-risk biopharmaceutical products share at least one attribute: the probability and impact of loss is manageable. Sentry BioPharma Services applies the same principles implemented across high-risk and high-value products to the management and protection of high-value APIs. Sentry’s experienced team strives to limit the probability and impact of loss, providing unparalleled protection for high-value ingredients. To learn more please visit API Management.
Regulatory oversight shapes every dimension of controlled substances: licensing, registration, storage, security, use, inventory and controlled drug disposal. The DEA licenses Sentry to store, distribute, manage returns, recall and manage destruction of Schedule III-V controlled substances. Sentry BioPharma Services provides the exacting care and management required to safeguard controlled substances which are brought into Sentry’s custody and care. To learn more please visit Controlled Substances.
Sentry's GMP pharmaceutical facility maintains active foreign trade zone (FTZ) status per Foreign Trade Zones Act 19 (U.S. Code Title 19, Chapter 1A). Sentry's active FTZ status and customs bond support import optimization and control of biological and pharmaceutical ingredients, materials, semi-finished and finished drug products.
Interestingly, a FTZ in the United States (US) is not technically considered a part of the US, and the same is true for foreign trade zones in other countries. To learn more please visit Foreign Trade Zone.
Sentry BioPharma Services’ maintains a GSA Logistics Worldwide Supply Schedule Contract, allowing us to respond to the unique logistic challenges of the federal government, while simultaneously providing GMP, best-in-class solutions. To learn more please visit GSA Schedule.
Secure vaccine storage and distribution services protect your inventory throughout the supply chain. Sentry’s guardianship ensures proper vaccine storage, rotation, accurate tracking and proper distribution of vaccines for routine fulfillment or pandemic response. To learn more please visit Vaccine Storage and Distribution.
For more information about how Sentry can implement a custom solution to meet your unique pharmaceutical supply chain challenges, contact Sentry via email or by phone at 1-866-757-7400, for a complimentary, no obligation phone call with one of Sentry's problem-solving experts.